Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paola Mapelli, Samuele Ghezzo, Ana Maria Samanes Gajate, Erik Preza, Giorgio Brembilla, Vito Cucchiara, Naghia Ahmed, Carolina Bezzi, Luca Presotto, Valentino Bettinardi, Annarita Savi, Patrizia Magnani, Raffaele Menichini, Angela Coliva, Ilaria Neri, Ettore Di Gaeta, Luigi Gianolli, Massimo Freschi, Alberto Briganti, Francesco De Cobelli, Paola Scifo, Maria Picchio
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
RM2
Acceso en línea:https://doaj.org/article/4ecd835d579a4984862cb5adb3863929
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4ecd835d579a4984862cb5adb3863929
record_format dspace
spelling oai:doaj.org-article:4ecd835d579a4984862cb5adb38639292021-11-25T17:21:21ZPreliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients10.3390/diagnostics111120682075-4418https://doaj.org/article/4ecd835d579a4984862cb5adb38639292021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2068https://doaj.org/toc/2075-4418The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing <sup>68</sup>Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with <sup>68</sup>Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, <sup>68</sup>Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by <sup>68</sup>Ga-PSMA, and <sup>68</sup>Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.Paola MapelliSamuele GhezzoAna Maria Samanes GajateErik PrezaGiorgio BrembillaVito CucchiaraNaghia AhmedCarolina BezziLuca PresottoValentino BettinardiAnnarita SaviPatrizia MagnaniRaffaele MenichiniAngela ColivaIlaria NeriEttore Di GaetaLuigi GianolliMassimo FreschiAlberto BrigantiFrancesco De CobelliPaola ScifoMaria PicchioMDPI AGarticlehybrid imagingPET/MRIPSMARM2prostate cancermultimodal imagingMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2068, p 2068 (2021)
institution DOAJ
collection DOAJ
language EN
topic hybrid imaging
PET/MRI
PSMA
RM2
prostate cancer
multimodal imaging
Medicine (General)
R5-920
spellingShingle hybrid imaging
PET/MRI
PSMA
RM2
prostate cancer
multimodal imaging
Medicine (General)
R5-920
Paola Mapelli
Samuele Ghezzo
Ana Maria Samanes Gajate
Erik Preza
Giorgio Brembilla
Vito Cucchiara
Naghia Ahmed
Carolina Bezzi
Luca Presotto
Valentino Bettinardi
Annarita Savi
Patrizia Magnani
Raffaele Menichini
Angela Coliva
Ilaria Neri
Ettore Di Gaeta
Luigi Gianolli
Massimo Freschi
Alberto Briganti
Francesco De Cobelli
Paola Scifo
Maria Picchio
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
description The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing <sup>68</sup>Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with <sup>68</sup>Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, <sup>68</sup>Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by <sup>68</sup>Ga-PSMA, and <sup>68</sup>Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.
format article
author Paola Mapelli
Samuele Ghezzo
Ana Maria Samanes Gajate
Erik Preza
Giorgio Brembilla
Vito Cucchiara
Naghia Ahmed
Carolina Bezzi
Luca Presotto
Valentino Bettinardi
Annarita Savi
Patrizia Magnani
Raffaele Menichini
Angela Coliva
Ilaria Neri
Ettore Di Gaeta
Luigi Gianolli
Massimo Freschi
Alberto Briganti
Francesco De Cobelli
Paola Scifo
Maria Picchio
author_facet Paola Mapelli
Samuele Ghezzo
Ana Maria Samanes Gajate
Erik Preza
Giorgio Brembilla
Vito Cucchiara
Naghia Ahmed
Carolina Bezzi
Luca Presotto
Valentino Bettinardi
Annarita Savi
Patrizia Magnani
Raffaele Menichini
Angela Coliva
Ilaria Neri
Ettore Di Gaeta
Luigi Gianolli
Massimo Freschi
Alberto Briganti
Francesco De Cobelli
Paola Scifo
Maria Picchio
author_sort Paola Mapelli
title Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
title_short Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
title_full Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
title_fullStr Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
title_full_unstemmed Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
title_sort preliminary results of an ongoing prospective clinical trial on the use of <sup>68</sup>ga-psma and <sup>68</sup>ga-dota-rm2 pet/mri in staging of high-risk prostate cancer patients
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/4ecd835d579a4984862cb5adb3863929
work_keys_str_mv AT paolamapelli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT samueleghezzo preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT anamariasamanesgajate preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT erikpreza preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT giorgiobrembilla preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT vitocucchiara preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT naghiaahmed preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT carolinabezzi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT lucapresotto preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT valentinobettinardi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT annaritasavi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT patriziamagnani preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT raffaelemenichini preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT angelacoliva preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT ilarianeri preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT ettoredigaeta preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT luigigianolli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT massimofreschi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT albertobriganti preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT francescodecobelli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT paolascifo preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
AT mariapicchio preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients
_version_ 1718412470211575808